To include your compound in the COVID-19 Resource Center, submit it here.

The changes in Scripps-Sandoz

WASHINGTON - The collaborative research agreement between Scripps Research Institute and Sandoz Pharmaceuticals Corp. has been transformed from a taxpayer rip-off to a model agreement, according to vocal critics of the original deal on Capital Hill and at NIH.

The new agreement is smaller in scope, gives Sandoz less control over Scripps and its scientists, and features innovative mechanisms for promoting technology transfer to small businesses.

The deal will take effect in 1997. Sandoz will provide Scripps with $20

Read the full 774 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers